Tumour Cell Line Development and Assays
At RoukenBio, our multidisciplinary team has a strong track record of designing and engineering tumour cell lines to custom specifications. Partner with us to enhance your project with a variety of ready to use immortalised cell lines to deliver rapid and effective solutions.
Tumour Cell Assay Service to Drive Your Programme Forward
We offer a wide range of advanced tumour cell assays and services to support your oncology research and therapeutic development. With access to tumour cells lines and through our custom cell engineering capabilities we are able to identify or generate cancer cell targets that are best suited to the needs of your study.
These cells can be incorporated into our customer and bespoke immune cell assays allowing the impact of your therapeutics to be assessed in an assay that is designed around your needs.
Our bespoke solutions are designed to provide comprehensive insights into tumour biology and facilitate the development of novel cancer therapies. Inspired by possibility, we embrace challenges as catalysts for innovation. So when the landscape shifts and many are struggling to maintain their balance, we’re always looking for new avenues to explore and novel solutions to implement to give your project the edge.
Assay Capabilities
Our tumour cell assay portfolio allows you to assess:
Immune-mediated tumour cell killing
In co-culture formats, supporting mechanisms such as T cell-directed cytotoxicity and Fc-mediated effector function (e.g., ADCC/ADCP) with kinetic and endpoint readouts depending on your question and modality.
Direct drug-mediated cytotoxicity
And growth inhibition, including ADC and small molecule-driven effects.
Target expression, antigen density and receptor modulation
Including engineered systems to model physiologic-to-pathological target ranges and support “on-target, off-tumour” risk assessments.
Target engagement and downstream signalling
Using fit-for-purpose approaches such as flow-based phenotyping, signalling readouts, and engineered reporter systems to link binding to function.
Advanced tumour models including 3D formats
E.g. tumoroid drug-response and immune-mediated tumoroid-killing assays) when increased physiological relevance is required.
Bespoke tumour cell assays
These capabilities can be delivered through both standardised and bespoke tumour cell assays, designed around your therapeutic modality and mechanism of action, and supported by high-content readouts.
Customisation and Cell Engineering Support
Where required, our team can develop engineered tumour cell lines to create highly specialised tumour cell line assays. This includes modifying target expression, inserting reporters, or generating stable cell systems that bring greater precision, sensitivity, and reproducibility to your readouts.
This can include:
- Modulating target expression (including defined or titratable expression ranges) to explore antigen density thresholds and functional activation windows.
- Unique advanced reporter and reporter gene combinations
- Gene editing (knockout/knock-in) to validate target/pathway dependence or to build cleaner mechanistic models.
- Stable cell system generation using targeted integration approaches for less time consuming and more efficient cell line development.
This cross-functional expertise ensures each model reflects the biology most relevant to your drug candidate – supporting data-driven decision-making from early discovery through IND-enabling studies.
Learn about our cell line development capabilities
We specialise in creating cell lines for cell-based functional assessments. Our bespoke solutions are designed to provide comprehensive insights into tumour biology and facilitate the development of novel cancer therapies. Inspired by possibility, we embrace challenges as catalysts for innovation.
ACCESS THE TECHNICAL PRESENTATION
